The FDA has approved UTEBZI (tebipenem pivoxil), the first oral penem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritis, who have limited or no alternative oral treatment options.
This approval raises an interesting question: Will oral tebipenem change the way we manage resistant urinary tract infections?
| Antibiotic | Route | Common Uses | Spectrum |
|---|---|---|---|
| Tebipenem pivoxil | Oral | cUTI, pyelonephritis | Broad Gram-negative activity, some Gram-positive coverage |
| Meropenem | IV | Sepsis, pneumonia, meningitis, complicated intra-abdominal infections, cUTIs | Very broad, including ESBL-producing organisms |
| Imipenem/Cilastatin | IV | Severe polymicrobial infections | Broad spectrum with good Gram-positive and anaerobic coverage |
| Ertapenem | IV/IM | ESBL UTIs, intra-abdominal infections, diabetic foot infections | Once-daily dosing; lacks activity against Pseudomonas aeruginosa and Acinetobacter |
| Doripenem | IV | Complicated UTIs and selected hospital-acquired infections | Excellent Gram-negative activity, including Pseudomonas |
Discussion: Would you consider using oral tebipenem as an early step-down therapy after initial IV carbapenem treatment in stable patients with ESBL-producing complicated UTIs? How do you think it compares with ertapenem for outpatient management?